Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease.

Yang,  Hyekyung; Park,  Cheol Young

doi:2018.19.2.88

J Korean Diabetes > Volume 19(2); 2018 > Article

Focused Issue

The Journal of Korean Diabetes 2018;19(2):88-96.
DOI: https://doi.org/10.4093/jkd.2018.19.2.88 Published online July 9, 2018.

혈당강하제를 통한 지방간 치료

양혜경, 박철영

Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease.

Hyekyung Yang, Cheol Young Park

¹Medical Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. cydoctor@chol.com
²Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from the pre-diabetic stage. Lifestyle intervention, including diet, exercise, and weight loss, is the primary recommended therapy for NAFLD. Among the therapeutic drugs for NAFLD treatment, anti-diabetic agents are aimed at improving or slowing the progression of NAFLD in addition to lowering blood glucose. In this paper, we systemically review the evidence surrounding antidiabetic medications and their ability to improve disease progression in patients with NAFLD.

Key Words: Diabetes mellitus, Glucose-lowering agents, Incretins, Nonalcoholic fatty liver disease, Sodium-glucose transporter 2, Thiazolidinediones